ArticleJournal of neuroinflammation2026
CXCL13⁺ CD4⁺ T cells are associated with B-cell recruitment and lesion progression in cerebral cavernous malformations.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cerebral cavernous malformations (CCMs) are neurovascular abnormalities associated with lifelong risks of intracranial hemorrhage (ICH), seizures, and neurologic deficits, affecting approximately 0.16%~0.8% of the general population. Although immune cell infiltration is well recognized as promoting CCM progression, the mechanisms underlying their recruitment into the lesion microenvironment remain poorly understood. In our study, we employed single-cell RNA sequencing (scRNA-seq) to identify a significant enrichment of a CD4⁺ T-cell subset producing CXCL13 and decipher the cellular crosstalk within CCMs. The CXCL13-producing CD4⁺ T cells exhibited enhanced interaction with CXCR5⁺ memory B cells, which showed upregulation of genes related to activation, persistence, and targeted migration. Immunohistochemical staining supported the spatial co-localization between CXCL13⁺ CD4⁺ T cells and CXCR5⁺ CD20⁺ B cells, as well as a positive association between their abundances, reinforcing this cellular crosstalk and suggesting a potential role for CXCL13 in shaping the inflammatory microenvironment and local adaptive immune responses. Clinically, elevated CXCL13 expression in CCM lesions was associated with a higher frequency of subacute ICH and B-cell infiltration in patients. Finally, in vivo experiments showed that administration of recombinant CXCL13 increased B-cell infiltration and Prussian blue staining-defined lesion bleeding, whereas blockade of CXCL13 attenuated CCM lesion development. Thus, our study identified a potentially pathogenic CXCL13
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.